Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study of Fluticasone Furoate (FF)/GW642444 Inhalation Powder and the Individual Components in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Type of subject: outpatient~* Informed consent: Subjects must give their signed and dated written informed consent to participate.~* Gender: Male or female subjects A female is eligible to enter and participate in the study if she is of:~* Non-child bearing potential OR~* Child bearing potential, has a negative pregnancy test at screening, and agrees to one of the acceptable contraceptive methods defined in the protocol~* Age: ≥40 years of age at Screening (Visit 1)~* COPD diagnosis: Subjects with a clinical history of COPD in accordance with the definition by the American Thoracic Society/European Respiratory Society \[Celli, 2004\]~* Tobacco use: Subjects with a current or prior history of ≥10 pack-years of cigarette smoking at Screening (Visit 1).~* Severity of Disease: Subjects with a Screening (Visit 1) measured post-albuterol/salbutamol:~* FEV1/FVC ratio of ≤0.70 and~* FEV1 ≤70% of predicted normal values~* Dyspnea: Achieved a score of ≥2 on the Modified Medical Research Council Dyspnea Scale (mMRC) at Screening (Visit 1).~Exclusion Criteria:~Subjects meeting any of the following criteria must not be enrolled in the study:~* Pregnancy: Women who are pregnant or lactating or are planning on becoming pregnant during the study.~* Asthma: Subjects with a current diagnosis of asthma~* α1-antitrypsin deficiency: Subjects with α1-antitrypsin deficiency as the underlying cause of COPD~* Other respiratory disorders: Subjects with active tuberculosis, lung cancer, bronchiectasis, sarcoidosis, lung fibrosis, pulmonary hypertension, interstitial lung diseases, or other active pulmonary diseases~* Lung resection: Subjects with lung volume reduction surgery within the 12 months prior to Screening (Visit 1)~* Chest X-ray (or CT scan): Subjects with a chest X-ray (or CT scan) that reveals evidence of clinically significant abnormalities not believed to be due to the presence of COPD.~* Hospitalization: Subjects who are hospitalized due to poorly controlled COPD within 12 weeks of Visit 1.~* Poorly controlled COPD: Subjects with poorly controlled COPD, defined as the occurrence of the following in the 6 weeks prior to Visit 1: Acute worsening of COPD that is managed by subject with corticosteroids or antibiotics or that requires treatment prescribed by a physician.~* Lower respiratory tract infection: Subjects with lower respiratory tract infection that required the use of antibiotics within 6 weeks prior to Visit 1.~* Other diseases/abnormalities: Subjects with historical or current evidence of clinically significant cardiovascular (i.e., pacemaker), neurological, psychiatric, renal, hepatic, immunological, endocrine (including uncontrolled diabetes or thyroid disease) or haematological abnormalities that are uncontrolled.~* Peptic Ulcer disease: Subjects with clinically significant peptic ulcer disease that is uncontrolled.~* Hypertension: Subjects with clinically significant hypertension that is uncontrolled.~* Cancer: Subjects with carcinoma that has not been in complete remission for at least 5 years. Carcinoma in situ of the cervix, squamous cell carcinoma and basal cell carcinoma of the skin would not be excluded if the subject has been considered cured within 5 years since diagnosis.~* Drug/food allergy: Subjects with a history of hypersensitivity to any of the study medication or components of the inhalation powder~* Drug/alcohol abuse: Subjects with a known or suspected history of alcohol or drug abuse within the last 2 years~* Medication prior to spirometry: Subjects who are medically unable to withhold their albuterol/salbutamol and/or their ipratropium 4 hours prior to spirometry testing at each study visit~* Additional medication: Use of certain medications such as bronchodilators and corticosteroids for the protocol-specified times prior to Visit 1 (the Investigator will discuss the specific medications)~* Oxygen therapy: Subjects receiving treatment with long-term oxygen therapy (LTOT) or nocturnal oxygen therapy required for greater than 12 hours a day. Oxygen prn use (i.e., ≤12 hours per day) is not exclusionary.~* Sleep apnea: Subjects with clinically significant sleep apnea who require use of continuous positive airway pressure (CPAP) device or non-invasive positive pressure ventilation (NIPPV) device.~* Pulmonary rehabilitation: Subjects who have participated in the acute phase of a Pulmonary Rehabilitation Program within 4 weeks prior to Screening (Visit 1) or who will enter the acute phase of a Pulmonary Rehabilitation Program during the study.~* Non-compliance: Subjects at risk of non-compliance, or unable to comply with the study procedures. Any infirmity, disability, or geographic location that would limit compliance for scheduled visits.~* Questionable validity of consent: Subjects with a history of psychiatric disease, intellectual deficiency, poor motivation or other conditions that will limit the validity of informed consent to participate in the study.~* Prior use of study medication/other investigational drugs~* Affiliation with investigator site: Study investigators, sub-investigators, study coordinators, employees of a participating investigator or immediate family members of the aforementioned are excluded from participating in this study.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Fluticasone Furoate Inhalation Powder (Type: EXPERIMENTAL): Inhaled Corticosteroid (ICS)
- FF Inhalation Pwdr (Type: EXPERIMENTAL): Inhaled Corticosteroid (ICS)
- Fluticasone Furoate/GW642444 Inhalation Powder (Type: EXPERIMENTAL): Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA)
- FF/GW642444 Inhalation Pwdr (Type: EXPERIMENTAL): Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA)
- GW642444 Inhalation Powder (Type: EXPERIMENTAL): Long Acting Beta Agonist(LABA)
- Placebo (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).